Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prime Editing of Alzheimer's Disease High-Risk APOE4 Allele by Brain-Directed Adeno-Associated Virus Vectors.

Human gene therapy - 1 May 2026

Günaydin Caner, Hackett Neil R, Wakim Victor, Sondhi Dolan, Kaminsky Stephen M, Crystal Ronald G

Abstract excerpt

Common variants of the apolipoprotein E (APOE) gene have a major impact on the risk of developing Alzheimer's disease (AD). Relative to homozygotes with the common E3 allele, the APOE4 variant (C112R) increases risk by 3.5-fold in E3/E4 heterozygotes and 15-fold in E4 homozygotes. Since the E3 and E4 alleles differ only by a single nucleotide, gene editing of E4 to E3 is a potential strategy to reduce AD risk in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Apolipoprotein E3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoprotein E4

Share to Dependovirus

Share to Gene Editing

Share to Genetic Therapy

Share to Genetic Vectors

Source

Identifiers

PMID: 41449667
DOI: 10.1177/10430342251401888

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prime Editing of Alzheimer's Disease High-Risk APOE4 Allele by Brain-Directed Adeno-Associated Virus Vectors.PMID 41449667Read ↗

Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models.Semantic proximity Read ↗

Efficient prime editing in mouse brain, liver and heart with dual AAVsSemantic proximity Read ↗

AAVrh.10 delivery of novel APOE2-Christchurch variant suppresses amyloid and Tau pathology in Alzheimer's disease mice.Semantic proximity Read ↗

AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's DiseaseSemantic proximity Read ↗

Neuronal APOE4 reduction with an APOE-I3-targeting ASO protects against neurodegeneration and neuroinflammation in an Alzheimer’s disease mouse modelSemantic proximity Read ↗

Successful Gene Editing of Apolipoprotein E4 to E3 in Brain of Alzheimer Model Mice After a Single IV Dose of Synthetic Exosome-Delivered CRISPRSemantic proximity Read ↗

AAV-based temporal APOE4-to-APOE2 replacement reveals rebound adaptation and RAB24-mediated Aβ and cholesterol dysregulationSemantic proximity Read ↗

Gene delivery of human apolipoprotein E alters brain Aβ burden in a mouse model of Alzheimer's diseaseSemantic proximity Read ↗

Silencing of <i>ApoE</i> with Divalent siRNAs Drives Activation of Immune Clearance Pathways and Improves Amyloid Pathology in Mouse Models of Alzheimer’s DiseaseSemantic proximity Read ↗

Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement miceSemantic proximity Read ↗

Silencing Apoe with divalent‐siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's diseaseSemantic proximity Read ↗

Generation of three isogenic, gene-edited iPSC lines carrying the APOE-Christchurch mutation into the three common APOE variants: APOE2Ch, APOE3Ch and APOE4Ch.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.